Home / Publication / Prediction of Olanzapine Exposure in Individual Patients Using Physiologically-based Pharmacokinetic Modeling and Simulation

Publication

Prediction of Olanzapine Exposure in Individual Patients Using Physiologically-based Pharmacokinetic Modeling and Simulation

Author(s): Thomas M. Polasek, Geoffrey T. Tucker, Michael J. Sorich, Michael D. Wiese, Titus Mohan, Amin Rostami-Hodjegan, Porntipa Korprasertthaworn, Vidya Perera, Andrew Rowland

Year: November 30, 2017

Recommended for you

Small Biotech Clinical Trial Application (CTA) & Investigational New Drug (IND) Submission Success with Integrated Project Management

Case Study

Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+/HER2− Metastatic Breast Cancer Data From the Phase 3 TROPiCS‐02 Trial

Publication

Model-Based Meta-Analysis (MBMA) at GSK: Real-World Impact on Strategy and Trials

Blog

Digital twins and virtual trials: A new era in rare disease drug development

Press Coverage

Prediction of Olanzapine Exposure in Individual Patients Using Physiologically-based Pharmacokinetic Modeling and Simulation

Prediction of Olanzapine Exposure in Individual Patients Using Physiologically-based Pharmacokinetic Modeling and Simulation

Small Biotech Clinical Trial Application (CTA) & Investigational New Drug (IND) Submission Success with Integrated Project Management

Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+/HER2− Metastatic Breast Cancer Data From the Phase 3 TROPiCS‐02 Trial

Model-Based Meta-Analysis (MBMA) at GSK: Real-World Impact on Strategy and Trials

Digital twins and virtual trials: A new era in rare disease drug development

Newsletter sign up

Quick links

Solutions

Contact